{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:48:11Z","timestamp":1777636091930,"version":"3.51.4"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103167","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T12:02:40Z","timestamp":1605182560000},"page":"103167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?"],"prefix":"10.1016","volume":"157","author":[{"given":"Eleonora","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Astara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pina","family":"Ziranu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Migliari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clelia","family":"Donisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Liscia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Impera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Persano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Tolu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Balconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Spanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annagrazia","family":"Pireddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Camera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Musio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Puzzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clelia","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Casadei Gardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0010","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2019.01182","article-title":"Oncolytic adenovirus\u2014a nova for gene-targeted oncolytic viral therapy in HCC","volume":"9","author":"Abudoureyimu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The role of cancer-associated fibroblasts and fibrosis in liver cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annu. Rev. Pathol."},{"issue":"40","key":"10.1016\/j.critrevonc.2020.103167_bib0020","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.103167_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818808086","article-title":"Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy","volume":"11","author":"Brar","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0030","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"10064","key":"10.1016\/j.critrevonc.2020.103167_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103167_bib0040","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-05-2856","article-title":"A phase I\/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides","volume":"12","author":"Butterfield","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0045","doi-asserted-by":"crossref","first-page":"e000442","DOI":"10.1136\/esmoopen-2018-000442","article-title":"Implementing TMB measurement in clinical practice: considerations on assay requirements","volume":"4","author":"B\u00fcttner","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2020.103167_bib0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.critrevonc.2018.06.017","article-title":"Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma","volume":"129","author":"Canale","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypi- can-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0060","doi-asserted-by":"crossref","first-page":"e0232449","DOI":"10.1371\/journal.pone.0232449","article-title":"The role of PNI to predict survival in advanced hepatocellular carcinoma treated with sorafenib","volume":"15","author":"Caputo","year":"2020","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103167_bib0065","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.2015.1102887","article-title":"Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib","volume":"16","author":"Casadei Gardini","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"issue":"41","key":"10.1016\/j.critrevonc.2020.103167_bib0070","doi-asserted-by":"crossref","first-page":"67142","DOI":"10.18632\/oncotarget.11565","article-title":"Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib","volume":"7","author":"Casadei Gardini","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.critrevonc.2020.103167_bib0075","doi-asserted-by":"crossref","first-page":"27988","DOI":"10.18632\/oncotarget.8569","article-title":"eNOS Polymorphisms and Clinical Outcome in Advanced HCC Patients Receiving Sorafenib: Final Results of the ePHAS Study","volume":"7","author":"Casadei Gardini","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103167_bib0080","doi-asserted-by":"crossref","first-page":"15243","DOI":"10.18632\/oncotarget.7444","article-title":"Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group","volume":"7","author":"Casadei Gardini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.103167_bib0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.09.003","article-title":"Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale","volume":"86","author":"Casadei Gardini","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"39","key":"10.1016\/j.critrevonc.2020.103167_bib0090","doi-asserted-by":"crossref","first-page":"66699","DOI":"10.18632\/oncotarget.19449","article-title":"Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review","volume":"8","author":"Casadei Gardini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.103167_bib0095","doi-asserted-by":"crossref","first-page":"42499","DOI":"10.1038\/srep42499","article-title":"Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study","volume":"7","author":"Casadei Gardini","year":"2017","journal-title":"Sci. Rep."},{"issue":"suppl. 4","key":"10.1016\/j.critrevonc.2020.103167_bib0100","article-title":"Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study","volume":"30","author":"Casadei Gardini","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0105","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3897","article-title":"Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study","author":"Casadei Gardini","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0110","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/OTT.S192572","article-title":"Profile of Lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all phase III trials","volume":"12","author":"Casadei Gardini","year":"2020","journal-title":"Onco. Ther."},{"issue":"3\u20134","key":"10.1016\/j.critrevonc.2020.103167_bib0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000501593","article-title":"Prognostic role of a new index (RAPID index) in advanced hepatocellular carcinoma patients receiving sorafenib: training and validation cohort","volume":"6","author":"Casadei-Gardini","year":"2019","journal-title":"Gastrointest. Tumors"},{"issue":"22","key":"10.1016\/j.critrevonc.2020.103167_bib0120","doi-asserted-by":"crossref","first-page":"e19958","DOI":"10.1097\/MD.0000000000019958","article-title":"Utility of neutrophil-to-Lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib","volume":"99","author":"Casadei-Gardini","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103167_bib0125","first-page":"301","article-title":"Chimeric antigen receptor-engineered T-cell therapy for liver cancer","volume":"17","author":"Chen","year":"2018","journal-title":"HBPD INT"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103167_bib0130","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","article-title":"Immunomodulatory TGF-b signaling in hepatocellular carcinoma","volume":"25","author":"Chen","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"issue":"suppl. 9","key":"10.1016\/j.critrevonc.2020.103167_bib0140","doi-asserted-by":"crossref","first-page":"ix186","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann. Oncol."},{"issue":"29","key":"10.1016\/j.critrevonc.2020.103167_bib0145","doi-asserted-by":"crossref","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0150","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.3390\/molecules19056393","article-title":"The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment","volume":"19","author":"D\u2019Anzeo","year":"2014","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0155","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s10620-017-4615-x","article-title":"Interplay between SIRT-3, metabolism and its tumor suppressor role in hepatocellular carcinoma","volume":"62","author":"De Matteis","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103167_bib0160","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/ijms20061503","article-title":"Role of SIRT-3, p-mTOR and HIF-1\u03b1 in hepatocellular carcinoma patients affected by metabolic dysfunctions and in chronic treatment with metformin","volume":"20","author":"De Matteis","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103167_bib0165","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11523-017-0522-5","article-title":"Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma","volume":"12","author":"Di Costanzo","year":"2017","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/EDBK_175230","article-title":"The promise of immunotherapy in the treatment of hepatocellular carcinoma","volume":"37","author":"El-Khoueiry","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"10088","key":"10.1016\/j.critrevonc.2020.103167_bib0180","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103167_bib0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ctrv.2010.08.001","article-title":"Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options","volume":"37","author":"Faloppi","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2407-14-110","article-title":"The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management","volume":"14","author":"Faloppi","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2020.103167_bib0195","doi-asserted-by":"crossref","first-page":"7196280","DOI":"10.1155\/2016\/7196280","article-title":"Lactate dehydrogenase in hepatocellular carcinoma: something old, something new","volume":"2016","author":"Faloppi","year":"2016","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11523-020-00698-x","article-title":"Angiogenesis genotyping and clinical outcomes in patients with advanced hepatocellular carcinoma receiving sorafenib: the ALICE-2 study","volume":"15","author":"Faloppi","year":"2020","journal-title":"Target. Oncol."},{"issue":"4, suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0205","article-title":"KEYNOTE-240: randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma","volume":"35","author":"Finn","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2020.103167_bib0210","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103167_bib0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0220","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGF\u03b2","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0225","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/hep.30337","article-title":"Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma","volume":"69","author":"Flynn","year":"2019","journal-title":"Hepatology"},{"issue":"10127","key":"10.1016\/j.critrevonc.2020.103167_bib0230","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0235","article-title":"A phase 3 study of durvalumab tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma: HIMALAYA study","volume":"36","author":"Furuse","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"suppl. 4","key":"10.1016\/j.critrevonc.2020.103167_bib0240","article-title":"Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"38","author":"Galle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103167_bib0245","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1517\/14728222.2015.1071354","article-title":"Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. is there a light at the end of the tunnel?","volume":"19","author":"Gnoni","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0250","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000496755","article-title":"Implications of immunotherapy in hepatobiliary tumours","volume":"35","author":"Gottlieb","year":"2019","journal-title":"Visc. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103167_bib0255","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0260","doi-asserted-by":"crossref","first-page":"e000394","DOI":"10.1136\/jitc-2019-000394","article-title":"Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Ho","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2\u20133","key":"10.1016\/j.critrevonc.2020.103167_bib0265","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcpa.2005.01.011","article-title":"Effects of gadolinium chloride (GdCl3) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions","volume":"133","author":"Ide","year":"2005","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0270","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"Ishizawa","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103167_bib0275","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3390\/cancers11121865","article-title":"Gene therapy for liver cancers: current status from basic to clinics","volume":"11","author":"Kamimura","year":"2019","journal-title":"Cancers"},{"issue":"7092","key":"10.1016\/j.critrevonc.2020.103167_bib0280","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0285","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4073","article-title":"Phase I\/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses","volume":"35","author":"Kelley","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103167_bib0290","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J. Exp. Med."},{"issue":"10126","key":"10.1016\/j.critrevonc.2020.103167_bib0295","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"suppl. 4","key":"10.1016\/j.critrevonc.2020.103167_bib0300","article-title":"Checkmate-040: nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status","volume":"37","author":"Kudo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4072","article-title":"First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100)","volume":"37","author":"Kudo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","article-title":"Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials","volume":"7","author":"LaRocca","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"suppl.5","key":"10.1016\/j.critrevonc.2020.103167_bib0315","first-page":"v851","article-title":"Randomised efficacy and safety results for atezolizumab (atezo) + bevacizumab (bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2020.103167_bib0320","first-page":"6428","article-title":"A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin","volume":"61","author":"Li","year":"2001","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103167_bib0325","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0330","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0335","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.dld.2019.06.017","article-title":"Hepatotoxicity of immune check point inhibitors: approach and management","volume":"51","author":"Lleo","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0340","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.510310111","article-title":"Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma","volume":"31","author":"Llovet","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103167_bib0345","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2020.103167_bib0350","doi-asserted-by":"crossref","first-page":"33897","DOI":"10.18632\/oncotarget.15406","article-title":"Immunotherapeutic approaches for hepatocellular carcinoma","volume":"8","author":"Longo","year":"2017","journal-title":"Oncotarget"},{"issue":"36","key":"10.1016\/j.critrevonc.2020.103167_bib0355","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.3748\/wjg.v24.i36.4152","article-title":"Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and\/or prognostic markers?","volume":"24","author":"Marisi","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103167_bib0360","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cancers11071023","article-title":"ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib","volume":"11","author":"Marisi","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0365","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2005.00.463","article-title":"Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas","volume":"23","author":"Mazzolini","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0370","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103167_bib0375","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103167_bib0380","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103167_bib0385","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103167_bib0390","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/hep.26429","article-title":"Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice","volume":"58","author":"Pradere","year":"2013","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103167_bib0395","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3110","article-title":"A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma","volume":"36","author":"Qin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"suppl. 8","key":"10.1016\/j.critrevonc.2020.103167_bib0405","article-title":"A-randomized-multicentered-phase-2-study-to-evaluate-SHR-1210-PD-1-antibody-in-subjects-with-advanced-hepatocellular-carcinoma-HCC-who-failed-or-intolerable-to-prior-systemic-treatment","volume":"29","author":"Qin","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103167_bib0410","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3-4","key":"10.1016\/j.critrevonc.2020.103167_bib0415","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000502714","article-title":"Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience","volume":"6","author":"Rovesti","year":"2019","journal-title":"Gastrointest. Tumors"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0420","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103167_bib0425","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/cgt.2010.40","article-title":"A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma","volume":"17","author":"Sangro","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0430","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"issue":"15, suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0435","article-title":"A randomized, multicenter, phase 3 study of nivolumab vs. sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459","volume":"34","author":"Sangro","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0440","doi-asserted-by":"crossref","first-page":"e105268","DOI":"10.1371\/journal.pone.0105268","article-title":"Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey","volume":"9","author":"Santini","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.critrevonc.2020.103167_bib0445","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0450","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1756-9966-29-164","article-title":"Trans-arterial chemo-embolization (TACE), with either lipiodol (Traditional TACE) or drug-eluting microspheres (Precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis","volume":"29","author":"Scartozzi","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103167_bib0455","doi-asserted-by":"crossref","first-page":"e32653","DOI":"10.1371\/journal.pone.0032653","article-title":"The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management","volume":"7","author":"Scartozzi","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0460","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ijc.28772","article-title":"VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study","volume":"135","author":"Scartozzi","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103167_bib0465","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed cell death protein\u20101 (PD\u20101)\u2010targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real\u2010world cohort","volume":"49","author":"Scheiner","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103167_bib0470","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-\u03b2 signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103167_bib0475","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103167_bib0480","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/cancers11121926","article-title":"Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers","volume":"11","author":"Tai","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0485","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4071","article-title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)","volume":"35","author":"Wainberg","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103167_bib0490","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103167_bib0495","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103167_bib0500","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1089\/hum.2010.219","article-title":"Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma","volume":"22","author":"Wei","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0505","article-title":"Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma","author":"Wong","year":"2020","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103167_bib0510","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"15, suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0515","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"37","author":"Yau","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"suppl. 5","key":"10.1016\/j.critrevonc.2020.103167_bib0520","first-page":"v851","article-title":"CHECKMATE 459: a randomized, multi-center phase 3 study of nivolumab (nivo) vs sorafenib (sor) as first-line (1l) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4, suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0525","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"38","author":"Yau","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103167_bib0530","doi-asserted-by":"crossref","first-page":"5198798","DOI":"10.1155\/2017\/5198798","article-title":"Oncolytic virus-based immunotherapies for hepatocellular carcinoma","volume":"2017","author":"Yoo","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2020.103167_bib0535","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10875-013-9976-0","article-title":"A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma","volume":"34","author":"Yu","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103167_bib0540","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/hum.2017.114","article-title":"Doubledose adenovirus-mediated adjuvant gene therapy improves liver transplantation outcomes in patients with advanced hepatocellular carcinoma","volume":"29","author":"Zhu","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103167_bib0545","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103167_bib0550","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"issue":"15, suppl","key":"10.1016\/j.critrevonc.2020.103167_bib0555","article-title":"Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)","volume":"37","author":"Zhu","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820303036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820303036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:40:34Z","timestamp":1760902834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820303036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":111,"alternative-id":["S1040842820303036"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103167","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103167"}}